Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

What's Going On With ImmunoGen Shares Today?

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.

Benzinga · May 23, 2022

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Benzinga · May 23, 2022

Seagen Posts Encouraging Data From Tucatinib Combo Trial In Colorectal Cancer

Seagen Inc (NASDAQ:SGEN) announced topline results from phase 2 MOUNTAINEER trial investigating Tukysa (tucatinib) in combination with trastuzumab in previously treated HER2-positive metastatic colorectal cancer (mCRC) patients. Trastuzumab is sold under the name Herceptin by Genentech, a unit of Roche Holdings AG (OTC:RHHBY). Data from this trial will form the basis of a planned supplemental…

Benzinga · May 23, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Innoviva Acquires AstraZeneca-Spin Off At $2.20/Share

Innoviva Inc (NASDAQ:INVA) has agreed to acquire Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) at $2.20 per share in cash. Innoviva currently owns approximately 60% of the outstanding shares of Entasis common stock. The acquisition consideration values Entasis' equity at $113 million on a fully diluted basis. "This acquisition will build upon our overall strategy to acquire differentiated,…

Benzinga · May 23, 2022

Why Nymox Pharma Shares Sinking to 52-Week Low?

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has received a Refusal to File (RTF) letter from FDA regarding its marketing application for Fexapotide Triflutate. Nymox's position is that clarifications remain to be resolved at a follow-up meeting and that some significant inconsistencies were involved. In March, the company submitted a Fexapotide Triflutate application for benign prostatic…

Benzinga · May 23, 2022

FDA Removes Clinical Hold On Ocugen's COVID Vaccine Trial

The FDA has lifted the clinical hold on Ocugen Inc's (NASDAQ:OCGN) Phase 2/3 trial, OCU-002, for Covaxin (BBV152), a whole virus inactivated COVID-19 vaccine candidate. In April, the agency paused the trials of the shot, Covaxin, after an inspection of a Bharat Biotech facility by the World Health Organization (WHO) revealed deficiencies…

Benzinga · May 23, 2022

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

Reuters · May 23, 2022

Read news from The Economist, FT, and more,
with one subscription

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

The Independent UK · May 23, 2022

Abbott CEO apologizes for the formula shortage as the first overseas shipment arrives

"We're sorry to every family we've let down," wrote CEO Robert Ford. The shuttered plant at the heart of the shortage will reopen in June, but it may take months before production is back to normal.

WEKU · May 22, 2022

Jif peanut butter products recalled over salmonella outbreak traced to Kentucky plant

Cases have been reported in 14 states

The Independent UK · May 22, 2022

Abbott CEO says ‘sorry’ over baby formula shortage and vows to ensure ‘this never happens again’

Chairman and CEO of the embattled company Robert Ford insists the company is taking steps ‘to ensure this never happens again’

The Independent UK · May 22, 2022

Popular peanut butter is recalled nationwide. It’s been linked to a salmonella outbreak

The U.S. Food and Drug Administration, along with Centers for Disease Control and Prevention, and others have been investigating a multistate outbreak of salmonella senftenberg infections and they are linked to a product so many of us enjoy daily.

McClatchy Washington Bureau · May 21, 2022

Jif peanut butter is being recalled for potential salmonella contamination

The J.M. Smucker Co. announced the recall on Friday. The Food and Drug Administration says current epidemiologic evidence points to a Lexington, Ky., facility as the likely cause of the outbreak.

WEKU · May 21, 2022

Formula scarcity spurs deeper questions

Corporate consolidation of baby formula-makers got us to this point of crisis

Salon · May 21, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK · May 21, 2022

Is Trump to blame for the baby formula shortage?

Reexamining a trade deal with bipartisan support

Tribune News Service · May 21, 2022

Amanda Little: US should follow the EU model for baby formula

Startup Bobbie introduced its infant formula product in January 2021, the first new brand to be approved for sale in nearly a decade. It was a small operator representing a tiny fraction of the $4 billion U.S. formula market, but when shortages began roiling the industry in recent months, Bobbie…

Los Angeles Times · May 21, 2022

Editorial: The shame of America’s baby-formula shortage

When the sudden COVID-19 shutdown caused people to hoard toilet paper, the nation was half amused by the inability to find a roll on any retail shelf.

Benzinga · May 20, 2022

6 Stocks To Watch Amid Monkeypox Outbreak

A Monkeypox outbreak has been reported in several European countries, two cases in Canada and one confirmed case in a man from Massachusetts.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · May 20, 2022

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

Benzinga · May 20, 2022

New FDA 510(k) Clearance Expands Anika's Sports Medicine Soft Tissue Portfolio

Anika Therapeutics Inc (NASDAQ:ANIK) has received FDA 510(k) clearance for the X-Twist Knotless Fixation System, a platform of suture anchors designed to be mechanically robust, easy to use, and support healing for critical repairs such as rotator cuff repair. According to SmartTRAK, nearly 670,000 rotator cuff procedures were performed in 2021, mainly in…

Benzinga · May 20, 2022

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy. AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

Benzinga · May 20, 2022

CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly And Co (NYSE:LLY) and Incyte Corporation's (NASDAQ:INCY) Olumiant (baricitinib) for severe alopecia areata (AA). If approved, Olumiant would be the first centrally-authorized oral treatment and first JAK inhibitor for severe AA in the European Union. …

Benzinga · May 20, 2022

Mid-Afternoon Market Update: Dow Dips Over 500 Points; Ross Stores Shares Slide

U.S. stocks extended losses toward the end of trading, with the Dow Jones dropping more than 500 points on Friday.

Benzinga · May 20, 2022

The Trials And Tribulations Of Psychedelic Research

This article by Natasha Sumner was originally published on Microdose and appears here with permission.

The Independent UK · May 20, 2022

Is Trump to blame for the baby formula shortage?

Reexamining a trade deal with bipartisan support

1 … 279 280 281 282

Coverage From

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Food and Drug Administration

620 stories

Centers for Disease Control and Prevention

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.